Seeking Alpha

Ahead of a biotech forum in San Francisco today, Forbes contributor Nathan Sadeghi-Nejad...

Ahead of a biotech forum in San Francisco today, Forbes contributor Nathan Sadeghi-Nejad examines the progress of cancer stem cells (CSC) in fighting tumors. Bulls think CSC therapies will "dramatically improve patient outcomes," while bears say that the data is "inconclusive or that expectations are unreasonably high." Sadeghi-Nejad is "somewhere in the middle." One listed player is Verastem (VSTM).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|